Literature DB >> 18628520

Steroid biomarkers and genetic studies reveal inactivating mutations in hexose-6-phosphate dehydrogenase in patients with cortisone reductase deficiency.

Gareth G Lavery1, Elizabeth A Walker, Ana Tiganescu, Jon P Ride, Cedric H L Shackleton, Jeremy W Tomlinson, John M C Connell, David W Ray, Anna Biason-Lauber, Ewa M Malunowicz, Wiebke Arlt, Paul M Stewart.   

Abstract

CONTEXT: Cortisone reductase deficiency (CRD) is characterized by a failure to regenerate cortisol from cortisone via 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1), resulting in increased cortisol clearance, activation of the hypothalamic-pituitary-axis (HPA) and ACTH-mediated adrenal androgen excess. 11beta-HSD1 oxoreductase activity requires the reduced nicotinamide adenine dinucleotide phosphate-generating enzyme hexose-6-phosphate dehydrogenase (H6PDH) within the endoplasmic reticulum. CRD manifests with hyperandrogenism resulting in hirsutism, oligo-amenorrhea, and infertility in females and premature pseudopuberty in males. Recent association studies have failed to corroborate findings that polymorphisms in the genes encoding H6PDH (R453Q) and 11beta-HSD1 (Intron 3 inserted adenine) interact to cause CRD.
OBJECTIVE: Our objective was to reevaluate the genetics and steroid biochemistry of patients with CRD.
DESIGN: We analyzed 24-h urine collection for steroid biomarkers by gas chromatography/mass spectrometry and sequenced the HSD11B1 and H6PD genes in our CRD cohort. PATIENTS: Patients included four cases presenting with hyperandrogenism and biochemical features clearly indicative of CRD.
RESULTS: Gas chromatography/mass spectrometry identified steroid biomarkers that correlated with CRD in each case. Three cases were identified as homozygous (R109AfsX3, Y316X, and G359D) and one case identified as compound heterozygous (c.960G-->A and D620fsX3) for mutations in H6PD. No mutations affecting enzyme activity were identified in the HSD11B1 gene. Expression and activity assays demonstrate loss of function for all reported H6PDH mutations.
CONCLUSIONS: CRD is caused by inactivating mutations in the H6PD gene, rendering the 11beta-HSD1 enzyme unable to operate as an oxoreductase, preventing local glucocorticoid regeneration. These data highlight the importance of the redox control of cortisol metabolism and the 11beta-HSD1-H6PDH pathway in regulating hypothalamic-pituitary-adrenal axis activity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18628520      PMCID: PMC2579651          DOI: 10.1210/jc.2008-0743

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  27 in total

1.  Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice.

Authors:  Nicholas M Morton; Janice M Paterson; Hiroaki Masuzaki; Megan C Holmes; Bart Staels; Catherine Fievet; Brian R Walker; Jeffrey S Flier; John J Mullins; Jonathan R Seckl
Journal:  Diabetes       Date:  2004-04       Impact factor: 9.461

2.  Variants implicated in cortisone reductase deficiency do not contribute to susceptibility to common forms of polycystic ovary syndrome.

Authors:  Nicole Draper; Brenda L Powell; Steve Franks; Gerard S Conway; Paul M Stewart; Mark I McCarthy
Journal:  Clin Endocrinol (Oxf)       Date:  2006-07       Impact factor: 3.478

3.  Apparent cortisone reductase deficiency: a rare cause of hyperandrogenemia and hypercortisolism.

Authors:  A Biason-Lauber; S L Suter; C H Shackleton; M Zachmann
Journal:  Horm Res       Date:  2000

4.  Apparent cortisone reductase deficiency: a unique form of hypercortisolism.

Authors:  G Phillipov; M Palermo; C H Shackleton
Journal:  J Clin Endocrinol Metab       Date:  1996-11       Impact factor: 5.958

5.  Lack of Association of the 11beta-hydroxysteroid dehydrogenase type 1 gene 83,557insA and hexose-6-phosphate dehydrogenase gene R453Q polymorphisms with body composition, adrenal androgen production, blood pressure, glucose metabolism, and dementia.

Authors:  Pauline Smit; Marieke J H J Dekker; Frank Jan de Jong; Annewieke W van den Beld; Jan W Koper; Huibert A P Pols; Albert O Brinkmann; Frank H de Jong; Monique M B Breteler; Steven W J Lamberts
Journal:  J Clin Endocrinol Metab       Date:  2006-10-24       Impact factor: 5.958

6.  Hexose-6-phosphate dehydrogenase confers oxo-reductase activity upon 11 beta-hydroxysteroid dehydrogenase type 1.

Authors:  Iwona J Bujalska; Nicole Draper; Zoi Michailidou; Jeremy W Tomlinson; Perrin C White; Karen E Chapman; Elizabeth A Walker; Paul M Stewart
Journal:  J Mol Endocrinol       Date:  2005-06       Impact factor: 5.098

Review 7.  Polycystic ovary syndrome.

Authors:  S Franks
Journal:  N Engl J Med       Date:  1995-09-28       Impact factor: 91.245

Review 8.  The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome.

Authors:  Héctor F Escobar-Morreale; Manuel Luque-Ramírez; José L San Millán
Journal:  Endocr Rev       Date:  2004-11-23       Impact factor: 19.871

Review 9.  11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response.

Authors:  Jeremy W Tomlinson; Elizabeth A Walker; Iwona J Bujalska; Nicole Draper; Gareth G Lavery; Mark S Cooper; Martin Hewison; Paul M Stewart
Journal:  Endocr Rev       Date:  2004-10       Impact factor: 19.871

10.  Defects in the HSD11 gene encoding 11 beta-hydroxysteroid dehydrogenase are not found in patients with apparent mineralocorticoid excess or 11-oxoreductase deficiency.

Authors:  H Nikkilä; G M Tannin; M I New; N F Taylor; G Kalaitzoglou; C Monder; P C White
Journal:  J Clin Endocrinol Metab       Date:  1993-09       Impact factor: 5.958

View more
  24 in total

Review 1.  Defects of steroidogenesis.

Authors:  A Biason-Lauber; M Boscaro; F Mantero; G Balercia
Journal:  J Endocrinol Invest       Date:  2010-02-24       Impact factor: 4.256

Review 2.  Role of a disordered steroid metabolome in the elucidation of sterol and steroid biosynthesis.

Authors:  Cedric H L Shackleton
Journal:  Lipids       Date:  2011-08-27       Impact factor: 1.880

Review 3.  The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders.

Authors:  Walter L Miller; Richard J Auchus
Journal:  Endocr Rev       Date:  2010-11-04       Impact factor: 19.871

4.  Mutations of the hexose-6-phosphate dehydrogenase gene rarely cause hyperandrogenemic polycystic ovary syndrome.

Authors:  Kenan Qin; Robert L Rosenfield
Journal:  Steroids       Date:  2010-11-02       Impact factor: 2.668

5.  The Role and Regulation of the 11 Beta-Hydroxysteroid Dehydrogenase Enzyme System in Patients with Inflammatory Bowel Disease.

Authors:  M Hussey; G Holleran; S Smith; Mark Sherlock; D McNamara
Journal:  Dig Dis Sci       Date:  2017-09-20       Impact factor: 3.199

6.  Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets.

Authors:  Claire E Knezevic; Gabriela Wright; Lily L Remsing Rix; Woosuk Kim; Brent M Kuenzi; Yunting Luo; January M Watters; John M Koomen; Eric B Haura; Alvaro N Monteiro; Caius Radu; Harshani R Lawrence; Uwe Rix
Journal:  Cell Chem Biol       Date:  2016-11-17       Impact factor: 8.116

Review 7.  Steroid biomarkers in human adrenal disease.

Authors:  Juilee Rege; Adina F Turcu; Tobias Else; Richard J Auchus; William E Rainey
Journal:  J Steroid Biochem Mol Biol       Date:  2019-01-29       Impact factor: 4.292

8.  11β-Hydroxysteroid dehydrogenase type-2 and type-1 (11β-HSD2 and 11β-HSD1) and 5β-reductase activities in the pathogenia of essential hypertension.

Authors:  Carmen Campino; Cristian A Carvajal; Javiera Cornejo; Betty San Martín; Oliviero Olivieri; Giancesare Guidi; Giovanni Faccini; Francesco Pasini; Javiera Sateler; Rene Baudrand; Lorena Mosso; Gareth I Owen; Alexis M Kalergis; Oslando Padilla; Carlos E Fardella
Journal:  Endocrine       Date:  2009-10-31       Impact factor: 3.633

Review 9.  Gas chromatography/mass spectrometry (GC/MS) remains a pre-eminent discovery tool in clinical steroid investigations even in the era of fast liquid chromatography tandem mass spectrometry (LC/MS/MS).

Authors:  Nils Krone; Beverly A Hughes; Gareth G Lavery; Paul M Stewart; Wiebke Arlt; Cedric H L Shackleton
Journal:  J Steroid Biochem Mol Biol       Date:  2010-04-22       Impact factor: 4.292

10.  Cortisone-reductase deficiency associated with heterozygous mutations in 11beta-hydroxysteroid dehydrogenase type 1.

Authors:  Alexander J Lawson; Elizabeth A Walker; Gareth G Lavery; Iwona J Bujalska; Beverly Hughes; Wiebke Arlt; Paul M Stewart; Jonathan P Ride
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.